The discovery of oncogenic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene, and sensitivity of mutant lung cancers to EGFR-TK inhibitors (TKIs), have revolutionized the treatment of advanced NSCLC. Here, EGFR is linked to lung carcinoma.